Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts
Sagimet Biosciences reported a Q3 GAAP EPS loss of -$0.40, missing estimates, but maintains strong momentum with Denifanstat's clinical progress. SGMT's cash position remains robust at $125.5 million, supporting clinical milestones into 2026 despite ongoing R&D-driven losses and disciplined operating spend. Denifanstat advances in Phase 1 combination studies for MASH and acne, with key data readouts expected in 2026 to drive further stock upside.
Sagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 Transcript
Sagimet Biosciences Inc. (NASDAQ:SGMT ) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants David Happel - CEO, President & Director Eduardo Martins - Chief Medical Officer Robert D'Urso - Senior Vice President of New Products Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Hello, everyone.
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?
Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
The heavy selling pressure might have exhausted for Sagimet Biosciences Inc. (SGMT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 437.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567
Sagimet Biosciences' partner Ascletis reported strong phase 3 results for denifanstat in moderate-to-severe acne, validating FASN inhibition as a novel oral treatment. Sagimet is advancing next-gen FASN inhibitor TVB-3567 for U.S. acne trials and planning a phase 1b combo study with denifanstat and resmetirom for MASH. The acne market is large and underserved, while FASN inhibition offers potential in both dermatology and metabolic disease, expanding SGMT's addressable market.
Sagimet Biosciences' Denifanstat Should Be Worth More Today
Denifanstat is SGMT's leading FASN inhibitor for MASH. It has shown strong Phase 2b results and earned the FDA Breakthrough Therapy designation. SGMT also has a diversified pipeline on acne, solid tumors, and GBM, enhancing its optionality beyond its primary MASH focus. They've recently shown some positive trial milestones, including the first Phase 3 dosing.
Sagimet: More Than Just A MASH Drug Development Biotech
Sagimet Biosciences Inc.'s Initiation of the phase 3 FASCINIT and FASCINATE-3 studies, using denifanstat for treatment of patients with MASH/MAFLD & MASH respectively, expected before the end of 2024. The global acne treatment market size is projected to grow from $17.48 billion by 2032. Results from phase 3 study by partner Ascletis, using denifanstat for treatment of patients with Acne Vulgaris, expected by Q2 of 2025.
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. Denifanstat's unique FASN inhibition mechanism effectively reduces liver fibrosis, positioning it as a superior treatment for advanced MASH compared to competitors like Tirzepatide. SGMT's robust financials, including $188.5 million in liquidity and no debt, provide a solid foundation for advancing Denifanstat through Phase 3 trials.
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
FDA's breakthrough therapy designation for SGMT's denifanstat for MASH with moderate-to-advanced liver fibrosis is based on phase IIb FASCINATE-2 study data.
Leerink Partnrs Weighs in on Sagimet Biosciences Inc.’s Q2 2024 Earnings (NASDAQ:SGMT)
Sagimet Biosciences Inc. (NASDAQ:SGMT – Free Report) – Analysts at Leerink Partnrs increased their Q2 2024 earnings per share (EPS) estimates for shares of Sagimet Biosciences in a research note issued to investors on Wednesday, May 15th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.35) per share for the quarter, up from their previous forecast of ($0.41). Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Sagimet Biosciences’ current full-year earnings is ($1.89) per share. Leerink Partnrs also issued estimates for Sagimet Biosciences’ Q3 2024 earnings at ($0.53) EPS, Q4 2024 earnings at ($0.77) EPS, FY2024 earnings at ($1.91) EPS, FY2025 earnings at ($3.64) EPS, FY2026 earnings at ($5.18) EPS, FY2027 earnings at ($7.22) EPS and FY2028 earnings at ($5.65) EPS. SGMT has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Sagimet Biosciences in a report on Thursday. SVB Leerink assumed coverage on Sagimet Biosciences in a report on Monday, March 25th. They set an “outperform” rating and a $26.00 price objective on the stock. JMP Securities decreased their price target on Sagimet Biosciences from $47.00 to $46.00 and set a “market outperform” rating on the stock in a report on Wednesday, February 7th. Finally, The Goldman Sachs Group decreased their price target on Sagimet Biosciences from $27.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $38.80. Check Out Our Latest Research Report on SGMT Sagimet Biosciences Stock Performance SGMT stock opened at $4.62 on Monday. Sagimet Biosciences has a 1-year low of $2.13 and a 1-year high of $20.71. The business has a 50 day simple moving average of $4.64 and a two-hundred day simple moving average of $5.64. Institutional Investors Weigh In On Sagimet Biosciences A number of institutional investors have recently added to or reduced their stakes in SGMT. Teacher Retirement System of Texas bought a new stake in Sagimet Biosciences during the third quarter valued at about $220,000. Platinum Investment Management Ltd. purchased a new stake in Sagimet Biosciences in the third quarter valued at about $3,378,000. Victory Capital Management Inc. purchased a new stake in Sagimet Biosciences in the third quarter valued at about $158,000. New York State Common Retirement Fund purchased a new stake in Sagimet Biosciences in the third quarter valued at about $56,000. Finally, FMR LLC purchased a new stake in Sagimet Biosciences in the third quarter valued at about $23,517,000. Institutional investors own 87.86% of the company’s stock. Insider Transactions at Sagimet Biosciences In related news, CEO David Happel acquired 12,100 shares of the company’s stock in a transaction that occurred on Tuesday, March 26th. The shares were bought at an average price of $5.27 per share, with a total value of $63,767.00. Following the completion of the transaction, the chief executive officer now directly owns 639,200 shares in the company, valued at $3,368,584. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 17.60% of the company’s stock. About Sagimet Biosciences (Get Free Report) Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.
